Drug-induced Hypersensitivity Syndrome / Drug Reaction with Eosinophilia and Systemic Symptoms. Part II. Diagnosis and Management.
DHR
DRESS
DiHS
SCAR
delayed hypersensitivity reaction
drug rash
drug reaction
drug reaction with eosinophilia and systemic symptoms
drug-induced hypersensitivity syndrome
eosinophilia
exanthem
exanthematous drug eruption
hypersensitivity
maculopapular eruption
morbilliform eruption
severe cutaneous adverse drug reaction
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
27 Jul 2023
27 Jul 2023
Historique:
received:
28
09
2022
revised:
11
02
2023
accepted:
17
02
2023
medline:
30
7
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
aheadofprint
Résumé
Drug-induced hypersensitivity syndrome (DiHS), also known as drug reaction with eosinophilia and systemic symptoms (DRESS), is a severe cutaneous adverse reaction (SCAR) characterized by an exanthem, fever, and hematologic and visceral organ involvement. The differential diagnosis includes other cutaneous adverse reactions, infections, inflammatory and autoimmune diseases, and neoplastic disorders. Three sets of diagnostic criteria have been proposed; however, consensus is lacking. The cornerstone of management is immediate discontinuation of the suspected drug culprit. Systemic corticosteroids remain first-line therapy, but the literature on steroid-sparing agents is expanding. Longitudinal evaluation for sequelae is recommended. Adjunctive tests for risk stratification and drug culprit identification remain under investigation. Part II of this continuing medical education activity begins by exploring the differential diagnosis and diagnosis of DiHS/DRESS and concludes with an evidence-based overview of evaluation and treatment.
Identifiants
pubmed: 37516356
pii: S0190-9622(23)02403-9
doi: 10.1016/j.jaad.2023.02.073
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023. Published by Elsevier Inc.